SANUWAVE Health, Inc. (SNWVD)
- Previous Close
17.00 - Open
18.00 - Bid 17.50 x 40000
- Ask 17.98 x 40000
- Day's Range
17.11 - 18.00 - 52 Week Range
1.72 - 22.46 - Volume
8,286 - Avg. Volume
3,012 - Market Cap (intraday)
150.436M - Beta (5Y Monthly) 1.20
- PE Ratio (TTM)
4.06 - EPS (TTM)
4.31 - Earnings Date Nov 8, 2024 - Nov 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's pulsed acoustic cellular expression systems, including dermaPACE system for treating diabetic foot ulcers and other chronic wounds; orthoPACE system for treating tendinopathies and acute and nonunion fractures; and Profile is used to provide solution for pain management in sports medicine and physical therapy. Its portfolio of wound treatment solutions provides patients with a noninvasive technology that boosts the body's normal healing and tissue regeneration processes. In addition, the company offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds. SANUWAVE Health, Inc. was founded in 2004 and is headquartered in Eden Prairie, Minnesota.
sanuwave.comRecent News: SNWVD
View MorePerformance Overview: SNWVD
Trailing total returns as of 10/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SNWVD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SNWVD
View MoreValuation Measures
Market Cap
150.44M
Enterprise Value
180.93M
Trailing P/E
4.07
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.23
Price/Book (mrq)
--
Enterprise Value/Revenue
7.27
Enterprise Value/EBITDA
15.24
Financial Highlights
Profitability and Income Statement
Profit Margin
-13.79%
Return on Assets (ttm)
4.50%
Return on Equity (ttm)
--
Revenue (ttm)
24.9M
Net Income Avi to Common (ttm)
-3.43M
Diluted EPS (ttm)
4.31
Balance Sheet and Cash Flow
Total Cash (mrq)
2.46M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-8.44M